{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:41:53Z","timestamp":1760838113419,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bmc.2019.115208","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T08:55:25Z","timestamp":1573462525000},"page":"115208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Synthesis and evaluation of 2\u2032-dihalo ribonucleotide prodrugs with activity against hepatitis C virus"],"prefix":"10.1016","volume":"28","author":[{"given":"A.","family":"Chris Krueger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff T.","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard R.","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Marvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Voight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.J.","family":"Bow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Van Handel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Peterkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DeAnne","family":"Stolarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Dekhtyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodger F.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"DeGoey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.115208_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.12351","article-title":"The present and future disease burden of hepatitis C virus (HCV) infections with today\u2019s 3 treatment paradigm. - volume 2","volume":"22","author":"Hatzakis","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.bmc.2019.115208_b0010","unstructured":"Centers for disease control and prevention website\u2013www.cdc.gov\/hepatitis\/statistics\/; see press release https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2016\/hcv-press-release.html."},{"key":"10.1016\/j.bmc.2019.115208_b0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distrubition and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2019.115208_h0020","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2019.115208_h0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/jvh.12825","article-title":"Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens","volume":"25","author":"Bhardwaj","year":"2018","journal-title":"J Viral Hepatitis"},{"key":"10.1016\/j.bmc.2019.115208_h0030","first-page":"482","article-title":"Benefit-risk assessment for sofosbuvir\/velpatasvir\/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration\u2019s evaluation","volume":"67","author":"Struble","year":"2018","journal-title":"Hepatology (Hoboken, NJ, U. S.)"},{"key":"10.1016\/j.bmc.2019.115208_h0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apt.14423","article-title":"Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naive chronic hepatitis C: Patient-reported outcomes from POLARIS 2 and 3","volume":"47","author":"Younossi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bmc.2019.115208_h0040","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3226","article-title":"Retreatment with sofosbuvir\/velpatasvir in cirrhotic patients with genotype 4 who failed a previous interferon-free regimen: A case series","author":"Boglione","year":"2018","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.bmc.2019.115208_h0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2019.115208_h0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13318-017-0428-8","article-title":"Pharmacokinetic interactions and safety of coadministration of glecaprevir and pibrentasvir in healthy volunteers","volume":"43","author":"Lin","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bmc.2019.115208_h0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cpdd.350","article-title":"Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first-in-human study","volume":"7","author":"Lin","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bmc.2019.115208_h0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2019.115208_h0065","doi-asserted-by":"crossref","unstructured":"Sofia MJ. Sofosbuvir: the discovery of a curative therapy for the treatment of hepatitis C virus. Successful Drug Discovery, 2. p. 163\u201388. DOI: 10.1002\/9783527800315.ch8.","DOI":"10.1002\/9783527800315.ch8"},{"key":"10.1016\/j.bmc.2019.115208_h0070","doi-asserted-by":"crossref","unstructured":"Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opinion on Drug Discovery, 10. p. 1363\u201377. DOI: 10.1517\/17460441.2015.1094051.","DOI":"10.1517\/17460441.2015.1094051"},{"key":"10.1016\/j.bmc.2019.115208_h0075","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.jhep.2014.09.006","article-title":"Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C","volume":"61","author":"Kumar","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2019.115208_b0035","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1021\/cr5002035","article-title":"Synthesis of nucleoside phosphate and phosphonate prodrugs","volume":"114","author":"Pradere","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2019.115208_b0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2013.11.008","article-title":"Chutes and ladders in hepatitis C nucleoside drug development","volume":"102","author":"Coats","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2019.115208_h0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1126\/science.1259210","article-title":"Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase","volume":"347","author":"Appleby","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bmc.2019.115208_h0095","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain terminating ribonucleoside analogs that inhibit hepatitis C virus replication. in Vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2019.115208_h0100","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/j.bmcl.2017.05.075","article-title":"Discovery of \u03b2 -D-2\u2019-deoxy-2\u2019-dichlorouridine nucleotide prodrugs as potent inhibitors of hepatitis C virus replication","volume":"27","author":"Pinho","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115208_h0105","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1016\/j.bmcl.2017.10.024","article-title":"Synthesis and anti-HCV activity of a series of \u03b2 -D-2\u2019-deoxy-2\u2019-dibromo nucleosides and their corresponding phosphoramidate prodrugs","volume":"27","author":"Chen","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115208_h0110","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1021\/acs.jmedchem.7b00067","article-title":"2\u2019-Chloro,2\u2019-fluoro ribonucleotide prodrugs with potent pan-genotypic activity against hepatitis C virus replication in culture","volume":"60","author":"Zhou","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115208_h0115","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1021\/acs.jmedchem.8b01300","article-title":"Discovery of a series of 2\u2019- \u03b1 -fluoro,2\u2019- \u03b2 -bromo-ribonucleosides and their phosphoramidate prodrugs as potent pan-genotypic inhibitors of hepatitis c virus","volume":"62","author":"Mengshetti","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115208_b0055","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.1021\/jo900637f","article-title":"Diastereo-controlled electrophilic fluorinations of 2-deoxyribonolactone: syntheses of all corresponding 2-deoxy-2-fluoro-lactones and 2'-deoxy-2'-fluoro-NAD+s","volume":"74","author":"Cen","year":"2009","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2019.115208_b0060","unstructured":"A mixture of halogenated products were generated and the ratio was determined by 1H NMR as 5a: C2-epi:5e:5f\u223c17:5:2:1."},{"key":"10.1016\/j.bmc.2019.115208_b0065","unstructured":"Chiral SFC analysis of the products determined 85% 9a and 14% 9e."},{"key":"10.1016\/j.bmc.2019.115208_b0070","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1023\/B:RUGC.0000025163.67206.ed","article-title":"Preparative synthesis of N-bromohexamethyldisilazane","volume":"73","author":"Rakhlin","year":"2003","journal-title":"Russian J General Chem"},{"key":"10.1016\/j.bmc.2019.115208_b0075","unstructured":"Kalayanov G, Torssell S, Wahling H. Preparation of nucleotides as hepatitis C virus polymerase inhibitors US 20150175648A1."},{"key":"10.1016\/j.bmc.2019.115208_b0080","unstructured":"Chau J, Chen HJ, DeGoey DA, et al. Anti-viral compounds US 10053474 \u03922."},{"key":"10.1016\/j.bmc.2019.115208_b0085","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1021\/acs.joc.8b02341","article-title":"Synthesis of ABBV-168, a 2'-bromouridine for the treatment of hepatitis C","volume":"84","author":"Voight","year":"2019","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2019.115208_b0090","unstructured":"Barreca G, Rasparini M, Poggiali M, et al. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof PCT Int. Appl. WO2016151542A1."},{"key":"10.1016\/j.bmc.2019.115208_b0095","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2019.115208_b0100","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1016\/j.bmcl.2017.08.029","article-title":"The discovery of IDX21437: design, synthesis and antiviral evalution of a 2\u2019- \u03b1 -chloro2\u2019-\u03b2 -c-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors","volume":"27","author":"Alexandre","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115208_b0105","unstructured":"Randolph JT, Li T, Krueger AC, et al., Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors, submitted to Bioorg Med Chem Lett."},{"key":"10.1016\/j.bmc.2019.115208_b0110","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2019.115208_b0115","unstructured":"Compound 16c is described in a recent publication by other researchers.10d The data we report for 16c agrees well with data included in that publication."},{"key":"10.1016\/j.bmc.2019.115208_b0120","unstructured":"Bruker AXS Inc., APEX2,version 2014.11-0, Madision Wisconsin; 2014."},{"key":"10.1016\/j.bmc.2019.115208_b0125","unstructured":"Sheldrick GM. University of G\u00f6ttingen, Germany; 1998."},{"key":"10.1016\/j.bmc.2019.115208_b0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jviromet.2007.05.016","article-title":"A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations","volume":"145","author":"Middleton","year":"2007","journal-title":"J Virol Methods"},{"key":"10.1016\/j.bmc.2019.115208_b0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.antiviral.2006.07.005","article-title":"Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera","volume":"73","author":"Tripathi","year":"2007","journal-title":"Antiviral Res"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808961931689X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808961931689X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:09:04Z","timestamp":1760836144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808961931689X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S096808961931689X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115208","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of 2\u2032-dihalo ribonucleotide prodrugs with activity against hepatitis C virus","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115208"}}